CMV-FLAG-GFP-CD63 Lentivirus

Lentiviral vectors are gene delivery vehicles derived from the human immunodeficiency virus (HIV). To prevent the production of replication-competent viruses, the HIV-1 genome is packaged into separate plasmids and co-transfected into cells, resulting in a lentiviral vector that is only capable of single infection and lacks replication. Lentiviral vectors have evolved from two-plasmid systems to four-plasmid systems, with increasing safety. The four-plasmid system is currently the most commonly used and has a wider range of applications, such as gene editing, gene therapy, transgenic animals, drug research, and CAR-T cell therapy.

Lentiviral vectors have a wide range of hosts and can infect both dividing and non-dividing cells. They can significantly improve the transduction efficiency of target genes in difficult-to-transfect cells, such as primary cells, stem cells, and undifferentiated cells. Lentiviruses can effectively integrate exogenous genes into cell chromosomes, achieving sustained, efficient, and stable expression in target cells. Lentiviral vectors can also carry target genes larger than 5 kb, allowing cDNA to be cloned into the lentiviral vector. CAR-T cell therapy has been clinically successful in treating various cancers and remains a hot topic in current medical research. The CAR-T production process primarily involves T cell enrichment, differentiation, and expansion, CAR gene transfer via viral or non-viral vectors, and then in vitro CAR-T cell expansion to produce the cell product. Therefore, the viral vector that delivers the specific CAR gene into T cells is a key raw material in the entire production process. Currently, most CAR-T cell production utilizes lentiviral vectors.